Skip to main content
Fig. 2 | Cost Effectiveness and Resource Allocation

Fig. 2

From: Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system

Fig. 2

Changes in DAS28-ESR and CDAI between baseline and 24 weeks. Remission rates according to DAS28-ESR were 76.4% in the bDMARDs, 63.6% in MTX, and 60.7% in the control group, respectively (above). Remission rates at 24 wee1ks according to CDAI were 45.4% in the bDMARDs, 24.2% in MTX, and 21.4% in the control group, respectively (below)

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us